1. Everolimus
   Jens Hasskarl, 2018, Small Molecules in Oncology CrossRef
2. Expression of total and phospho 4EBP1 in metastatic and non‑metastatic renal cell carcinoma
   Sei Naito et al, 2019, Oncology Letters CrossRef
3. Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs)
   Zuo Du et al, 2018, Xenobiotica CrossRef
4. MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE
   Xin Lu et al, 2024, Open Medicine CrossRef
5. Clinical benefit of early treatment with bone‐modifying agents for preventing skeletal‐related events in patients with genitourinary cancer with bone metastasis: A multi‐institutional retrospective study
   Takuya Owari et al, 2019, International Journal of Urology CrossRef
6. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics
   Yunxia Wang et al, 2023, British Journal of Pharmacology CrossRef
7. Follicle inhibition at the primordial stage without increasing apoptosis, with a combination of everolimus, verapamil
   Michail Pargianas et al, 2020, Molecular Biology Reports CrossRef